Carlyle Q2 stocks medical supplies giant Medline (MDLN.US) and aviation maintenance giant StandardAero (SARO.US) to build a warehouse for new AI cloud manufacturer Nebius (NBIS.US)

The Zhitong Finance App learned that according to the US Securities and Exchange Commission (SEC) disclosure, global alternative asset management giant CARLYLE GROUP INC (CARLYLE GROUP INC) submitted a position report (13F) for the second quarter ending June 30, 2026.

According to statistics, the total market value of Carlyle's holdings in the second quarter was 10 billion US dollars. Compared with the total market value of the previous quarter, the total market value was about 10.6 billion US dollars, down 0.193% from the previous quarter. Carlyle added only 3 stocks to its US stock portfolio in the second quarter, increased its holdings by 2, reduced its holdings by 2, and cleared 4 stocks. Among them, the top ten holdings account for 99.94% of the total market value of Carlyle's holdings.

Among Carlyle's top ten stocks in Q2 2026, Medline (MDLN.US) was the most heavily held stock, holding about 187 million shares, with a market value of about US$7.379 billion, accounting for 73.78% of the portfolio. There was no change in the overall number of positions held in the previous quarter. According to information, Medline is the main distributor and manufacturer of medical surgical products. It provides about 335,000 products, and its business is divided into two major segments. The first is the “Medline Private Brand” section, which covers the company's own products and its own branded products; the second is the “Supply Chain Solutions” section, which is responsible for distributing medical supplies from third parties and providing logistics and procurement services to medical institutions.

StandardAero (SARO.US) is Carlyle's second-largest holdings, holding about 84.5870 million shares, with a market value of about US$2,530 billion, accounting for 25.30% of the portfolio. There is also no change in the overall number of holdings in the previous quarter. StandardAero is an established global aviation maintenance, repair and overhaul (MRO) service provider founded in 1911 and headquartered in Scottsdale, Arizona, USA. The company focuses on aero engine aftermarket services, covering fixed-wing and rotary-wing (helicopter) fleets, and serves commercial aviation, business jet/commercial aviation, and military aviation.

Phathom Pharmaceuticals (PHAT.US) is Carlyle's third-largest holding of about 3.4968 million shares, with a market value of about US$379.404 million, accounting for 0.38% of the portfolio. There was no change in the overall number of holdings in the previous quarter. Phathom Pharmaceuticals is a biopharmaceutical company focusing on gastrointestinal (GI) acid-related diseases. It focuses on developing and commercializing vonoprazan, a potassium-competitive acid blocker (PCAB), and has exclusive rights in this mechanism in specific indications in Europe, America, and Canada.

Invitation Homes Inc (INVH.US), an American real estate company that focuses on single-family rental, is Carlyle's fourth largest holding, holding 662,900 shares, with a market value of about US$2.062 million, accounting for 0.20% of the portfolio, a decrease of 0.18% from the total number of holdings held in the previous quarter.

China's autonomous driving company PONY.US (PONY.US) is Carlyle's fifth largest holding stock, holding about 2.3624 million shares, with a market value of about US$16.419 million, accounting for 0.16% of the investment portfolio. There was no change in the overall number of positions held in the previous quarter.

Judging from changes in position ratios, Carlyle's top five purchases in the second quarter were: SunPower (SPWR.US), Riley Exploration Permian (REPX.US), AI cloud vendor Nebius Group NV (NBIS.US), Ramaco Resources (METC.US), and Robinhood Markets (HOOD.US), among which Riley Exploration Permian, Nebius, and Ramaco Resources opened new stock positions for Carlyle in the second quarter.

The top five sales targets were CubeSmart (CUBE.US), Q32 Bio (QTTB.US), Heartflow (HTFL.US), Spyre Therapeutics (SYRE.US), and Exicure (XCUR.US). Among them, CubeSmart, Exicure, Heartflow, and Spyre Therapeutics were cleared by Carlyle in the second quarter.